1. What are the benefits and risks of GLP1? Our new study in @naturemedicine comprehensively maps all the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By Yan Xie, Taeyoung Choi and me 🧵 nature.com/articles/s4159…

Let me address this. We wrote the grant to do this project in 2018. It was funded in 2020. We deliberately delayed this to devote time and effort to addressing Covid and Long Covid. My team and I remain committed to working on LC, but we cannot default on our other commitments.

🚨 New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (weight loss drugs) across 175 health conditions. 📄 Free access to the full study: rdcu.be/d6VYU 🧵 Explore the key findings: x.com/zalaly/status/…

🚨 I dive into the benefits and risks of Ozempic and similar weight loss drugs in this article for The Conversation U.S. 💊 These drugs may lower the risk of 42 health conditions but aren’t without risks theconversation.com/ozempic-and-si… Free PDF of original article rdcu.be/d6VYU

🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions. nature.com/articles/s4159…

Thanks to Derek Thompson for hosting me on his podcast. We talked about the GLP-1 and more. Details in this post below.

I talked to Dani Blum from The New York Times about the potential role of GLP-1 drugs on Alzheimer’s disease. They seem promising, but more data is needed for sure. nytimes.com/2025/01/31/wel…

Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés My Ozempic piece has been translated into French; thanks the amazing team at Conversation in Paris. The Conversation France theconversation.com/alzheimer-addi…

New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics. Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues. nordforsk.org/2025/knowledge…

This thread is a great explainer of our paper on the benefits and risks GLP-1 drugs nature.com/articles/s4159… Thanks F. Perry Wilson, MD MSCE for this informative thread.

GLP-1 drugs are revolutionizing the way we think about obesity. It is a chronic disease (like high blood pressure), and might actually be a form of food addiction. One reason these drugs are so effective in treating obesity could be that they address the underlying addiction. We

Honored to speak at Harvard University’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing